Morning Overview on MSN
A massive long-term review just tied GLP-1 weight-loss drugs to sharply lower rates of heart attacks, strokes, heart failure, and early death
When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what ...
First-in-class drugs can be highly innovative because of their novel mechanisms of action, but they also carry uncertainty in the absence of clinical experience. To understand how such drugs advance ...
Prescription Drug Affordability Boards (PDABs) are becoming a larger part of the state drug price regulatory landscape. 1 The boards are regulatory bodies that review the affordability and cost of ...
Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...
School of Pharmacy, Fudan University, Pudong, Shanghai, China. In 2024, the China National Medical Products Administration (NMPA) approved a total of 228 new drug applications (NDAs), including 123 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results